key: cord-0941833-jp330b4t
authors: Yusof, Wardah; Irekeola, Ahmad Adebayo; Wada, Yusuf; Engku Abd Rahman, Engku Nur Syafirah; Ahmed, Naveed; Musa, Nurfadhlina; Khalid, Muhammad Fazli; Rahman, Zaidah Abdul; Hassan, Rosline; Yusof, Nik Yusnoraini; Yean Yean, Chan
title: A Global Mutational Profile of SARS-CoV-2: A Systematic Review and Meta-Analysis of 368,316 COVID-19 Patients
date: 2021-11-11
journal: Life (Basel)
DOI: 10.3390/life11111224
sha: 6191b3559369345fbd05aa5de4e269f9505c6294
doc_id: 941833
cord_uid: jp330b4t

Since its first detection in December 2019, more than 232 million cases of COVID-19, including 4.7 million deaths, have been reported by the WHO. The SARS-CoV-2 viral genomes have evolved rapidly worldwide, causing the emergence of new variants. This systematic review and meta-analysis was conducted to provide a global mutational profile of SARS-CoV-2 from December 2019 to October 2020. The review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA), and a study protocol was lodged with PROSPERO. Data from 62 eligible studies involving 368,316 SARS-CoV-2 genomes were analyzed. The mutational data analyzed showed most studies detected mutations in the Spike protein (n = 50), Nucleocapsid phosphoprotein (n = 34), ORF1ab gene (n = 29), 5′-UTR (n = 28) and ORF3a (n = 25). Under the random-effects model, pooled prevalence of SARS-CoV-2 variants was estimated at 95.1% (95% CI; 93.3–96.4%; I(2) = 98.952%; p = 0.000) while subgroup meta-analysis by country showed majority of the studies were conducted ‘Worldwide’ (n = 10), followed by ‘Multiple countries’ (n = 6) and the USA (n = 5). The estimated prevalence indicated a need to continuously monitor the prevalence of new mutations due to their potential influence on disease severity, transmissibility and vaccine effectiveness.

Coronavirus Disease-19 is caused by Severe Acquired Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) [1, 2] . Since the SARS-CoV-2 epidemic first reported in Wuhan, China, the clinical features of COVID-19 have evolved, moving from clinically apparent pulmonary or flu-like symptoms to subclinical or even silent infections. The COVID-19 infection could frequently involve an asymptomatic or paucisymptomatic framework, leading to a spread in the general population [3] . COVID-19 produces respiratory distress with mild to severe symptoms, and it is fatal in individuals with a chronic disease or a compromised immune system [4] . Various clinical outcomes in COVID-19

Life 2021, 11, 1224 2 of 17 patients have also been documented throughout several other regions across the world. As of 29 September 2021, according to the World Health Organization (WHO), the SARS-CoV-2 pandemic has infected over 232,075,351 individuals across the world, resulting in 4,752,988 fatalities and significant disruptions to regular activities and national economies.

The international scientific community continuously characterized the pathophysiological features of COVID-19, developed diagnostic tools, evaluated immune responses, and identified risk factors for severe illness courses. SARS-CoV-2 clustered outbreaks and super spreading episodes provide a unique challenge to pandemic control [5] . However, the basic characteristics of SARS-CoV-2 genome evolution and transmission dynamics within the human population are still unknown [6] . COVID-19 infection demonstrated related inflammatory state of the upper airway mucosa and olfactory neurotoxic damage. However, to date, a reliable method in the evaluation of the nasal health of post-infection patients is not clear [7] .

SARS-CoV-2 genomic sequencing from several geographical regions has recently revealed that the virus quickly changes by accumulating mutations in its genome. It has been proposed that new SARS-CoV-2 variants may adapt better to new geographical locations, making them more potent than the virus that discovered in Wuhan, China.

All viruses' genomes gain mutations over time. However, various variables, including the mutation rate and the effects of mutation on viral dynamics within and between individual hosts, influence the rate of mutation accumulation and its repercussions for transmission and illness in the host population [8] . The combination of these variables determines the development and transmission of viral variations and the evolution of pandemics. Detection of mutations spread worldwide is essential for a better understanding of the viral evolution, bio-pathology and transmission since RNA virus genomes are highly susceptible to mutation [9] .

The Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocol (PRISMA-P 2015) guidelines [10] were used as this study's checklist. The study population included individuals with SARS-CoV-2 infection with the main out-come being mutations in the SARS-CoV-2. Reference was made to the Wuhan strain as a comparator A Prospero protocol (No CRD42021229620) was lodged for this study.

The PROSPERO database and Database of Abstracts of Reviews of Effects (DARE) (http://www.library.UCSF.edu; accessed on 10 January 2021) were searched to ensure no other meta-analysis on the impact of the mutational profile of SARS-CoV-2 on transmissibility and disease severity exists or is ongoing. The literature search was performed using international databases PubMed, Scopus, Science Direct and Google Scholar using the search terms listed in Table S2 . Two authors carried out the database search to minimize bias.

Inclusion criteria: (1) Studies reporting on human COVID-19, (2) Studies reporting on SARS-CoV-2 mutations, (3) Studies reporting on SARS-CoV-2 mutations and their association with superspreading events, transmissibility and severity of illness in COVID-19 patients. Exclusion criteria include reviews papers, animal studies, protein characterization studies, studies on environmental sampling, and media reports.

The methodological quality of the included studies was assessed independently by two authors using the Joanna Briggs Institute (JBI) critical appraisal checklist for prevalence data [11] . A score of '1' for "yes" and '0' for other parameters was assigned to attain a total Life 2021, 11, 1224 3 of 17 quality score ranging from '0' to '9'. Studies with an overall score of '7'-'9' were considered sufficient quality (Table S3) .

Two independent authors performed the data extraction by using standardized forms, which included manuscript title, authors, journal, publication year, countries of study, period of study, number of participants, number of mutated cases, regions of mutations, types of mutations, mutations, viral load, symptoms, severity (mild, moderate, severe, fatal), sample types (nasopharyngeal swab, bronchoalveolar lavage), viral shedding, comorbidity, mutation detection method, the database used (data downloaded), database accessed and transmissibility.

Studies that analyzed genetic mutations from more than one country were categorized as "multiple countries" rather than the individual countries included. When mutational data from different countries and regions were analyzed as a whole, instead of by specific countries, they were characterized as 'worldwide', and the data were extracted and analyzed in that form to avoid confusion. For regions of mutations labelled as ORF1a, ORF1b, nsp1-14, 3C-like proteinase, RNA-dependent RNA polymerase (RdRp), helicase, 3 -to-5 exonuclease, endoRNAse, 2 -O-ribose methyltransferase, or leader protein, they were characterized as 'ORF1ab' to simplify analysis. Where more than one article reported mutational data from the same group of sample, record, or patient cohort, only one was counted and selected.

Data analysis was conducted using Comprehensive Meta-analysis Software (CMA) (Version 2.0) (https://www.meta-analysis.com/; accessed on 25 July 2021). The pooled prevalence of SARS-CoV-2 variants was calculated and subgroup analysis was done according to country. A random-effect model using the DerSimonian-Laird method of the metaanalysis was employed to determine the pooled estimates of the reported SARS-CoV-2 variants and subtype proportions. A forest plot was subsequently generated to visually summarize details of the individual studies alongside the estimated common effect and degree of heterogeneity. Publication bias was examined using funnel plots (visual aid for detecting bias) and Egger's regression test. Cochran's Q test evaluated the heterogeneities (i.e., variation in study outcomes between studies) of study-level estimates and quantified using I 2 statistics. I 2 values of 25%, 50%, and 75% were considered low, moderate, and high heterogeneity, respectively [12] .

Subgroup meta-analysis was used to analyze sources of heterogeneity. A sensitivity test was conducted using the leave-one-out analysis. p-value of <0.001 was considered to be statistically significant for all tests.

The complete literature search process is displayed in Figure 1 . The search strategy initially found 352 articles, after which 325 were left after duplicates removal. Two hundred and fifty-three articles were excluded based on the exclusion criteria. The full-text of 72 articles were assessed for eligibility, and ten were excluded for lack of mutations data or mutations data were not countries-specified. A total of 62 articles were included in the final qualitative synthesis, and finally, 51 articles published between December 2019 and October 2020 were included in the final quantitative synthesis (meta-analysis). 

All the eligible studies included in the meta-analyses were of high methodological quality. From 62 studies included from December 2019 to October 2020 (Table 1) [2, , the highest numbers were from Worldwide (n = 10), multiple countries (n = 6) and the USA (n = 5). The 368,316 samples and genomic data analyzed in the studies were detected by quantitative Reverse Transcriptase (qRT-PCR) or DNA sequencing (Sanger, Next-generation, Whole-genome or Nanopore sequencing).

Genomic data from the studies included covered all regions of SAR-CoV-2 ( Figure  2 ). From the mutational data analysed, the studies detected mutations in the Spike (S) protein (n = 50), Nucleocapsid (N) phosphoprotein (n = 34), Open Reading Frame (ORF) 1ab gene (n = 29), 5′-Untranslated region (UTR) (n = 28), ORF3a (n = 25), Membrane (M) glycoprotein (n = 19), ORF7 (n = 10), ORF6 (n = 8), ORF8 (n = 8), ORF10 (n = 8), Envelope (E) protein (n = 7), 3′ UTR (n = 5) and ORF14 (n = 1). The synonymous and missense mutations detected, mostly based on countries and region of mutations, are listed in Table S1 . 

All the eligible studies included in the meta-analyses were of high methodological quality. From 62 studies included from December 2019 to October 2020 (Table 1) [2, , the highest numbers were from Worldwide (n = 10), multiple countries (n = 6) and the USA (n = 5). The 368,316 samples and genomic data analyzed in the studies were detected by quantitative Reverse Transcriptase (qRT-PCR) or DNA sequencing (Sanger, Nextgeneration, Whole-genome or Nanopore sequencing).

Genomic data from the studies included covered all regions of SAR-CoV-2 ( Figure 2 ). From the mutational data analysed, the studies detected mutations in the Spike (S) protein (n = 50), Nucleocapsid (N) phosphoprotein (n = 34), Open Reading Frame (ORF) 1ab gene (n = 29), 5 -Untranslated region (UTR) (n = 28), ORF3a (n = 25), Membrane (M) glycoprotein (n = 19), ORF7 (n = 10), ORF6 (n = 8), ORF8 (n = 8), ORF10 (n = 8), Envelope (E) protein (n = 7), 3 UTR (n = 5) and ORF14 (n = 1). The synonymous and missense mutations detected, mostly based on countries and region of mutations, are listed in Table S1 . 

The pooled prevalence of SARS-CoV-2 variants was estimated at 95.1% (95% CI; 9 96.4%; I 2 = 98.952%; p = 0.000) (Figure 3 ). Random-effects meta-analyses were carried Between-study variability was high (t 2 = 0.515; heterogeneity I 2 = 98.952% with heter neity chi-square (Q) = 4772.621, degrees of freedom (df) = 50, and p = 0.000). Moreo publication bias was observed, as shown in the asymmetrical funnel plot (Figure 4 ). U the Trim and Fill method and because the random-effects model was utilized, 22 mis studies were imputed to the left side of the mean effect ( Figure 5 ), resulting in a p estimate of 82.5% (95% CI; 77. 6-86.4 ). In addition to the funnel plots, Egger's test was u to confirm the extent of bias (t-value = 1.447; p = 0.07717). 

The pooled prevalence of SARS-CoV-2 variants was estimated at 95.1% (95% CI; 93.3-96.4%; I 2 = 98.952%; p = 0.000) (Figure 3 ). Random-effects meta-analyses were carried out. Between-study variability was high (t 2 = 0.515; heterogeneity I 2 = 98.952% with heterogeneity chi-square (Q) = 4772.621, degrees of freedom (df) = 50, and p = 0.000). Moreover, publication bias was observed, as shown in the asymmetrical funnel plot (Figure 4 ). Using the Trim and Fill method and because the random-effects model was utilized, 22 missing studies were imputed to the left side of the mean effect ( Figure 5 ), resulting in a point estimate of 82.5% (95% CI; 77. 6-86.4 ). In addition to the funnel plots, Egger's test was used to confirm the extent of bias (t-value = 1.447; p = 0.07717). 

The result of subgroup meta-analysis by country showed that the majority of the studies were conducted Worldwide (n = 10), followed by studies carried out in Multiple countries (n = 6) and the USA (n = 5). Interestingly, China with three studies had heterogeneity (I 2 ) of 5.356 and prevalence of 97.5% (CI = 85.1-99.6%), while Italy, with the same number of studies, had heterogeneity of 0.000 and prevalence of 98.1% (CI = 88.2-99.7%). Heterogeneity was highest among studies conducted Worldwide (I 2 = 99.747%), which was also trailed by six studies conducted in Multiple countries (I 2 = 95.168%) ( Table 2 ). The forest plot is shown in Figure 6 . 

Meta-regression was done for the single variable country. Method of moments was used as the computational option, and a scattered plot (Figure 7 ) was plotted. p-value of '0.000 was obtained for 'Country', indicating the heterogeneity observed in this study, aside from chance, could also be contributed by country. 

Meta-regression was done for the single variable country. Method of moments was used as the computational option, and a scattered plot (Figure 7 ) was plotted. P-value of '0.000′ was obtained for 'Country', indicating the heterogeneity observed in this study, aside from chance, could also be contributed by country 

With the high infection numbers worldwide, the SARS-CoV-2 virus has evolved, developed mutations and given rise to new genetic variations with increased infectivity and transmissibility. Efforts are currently being undertaken to characterize the virus and its genomic variability molecularly. Viral mutations and variants around the globe are routinely monitored through sequence-based surveillance, epidemiological analysis and laboratory studies.

This study has examined the mutational profile of SARS-CoV-2 between December 2019 to October 2020 from 62 studies of different continents. The pooled prevalence of SARS-CoV-2 variants in COVID-19 patients' samples estimated by the random-effect model was 95.1%. Upon using the Trim and Fill method to adjust for potential bias, the estimate for the prevalence of the variants was still very high at 82.5%.

The analysis showed that between-study variability was high (I 2 = 98.95%). The subgroup meta-analysis showed that the high heterogeneity was contributed by countries such 'Worldwide' (I 2 = 99.7%), 'Multiple Countries' (I 2 = 95.2%), Hong Kong (I 2 = 93.7%) and USA (I 2 = 92.3%). Only two countries, Italy (I 2 = 0%) and China (I 2 = 5.4%) showed a low heterogeneity score. The different methods used to detect the mutations may contribute to the high heterogeneity, especially in the 'Worldwide' and 'Multiple Countries'. The high heterogeneity could also be attributed to the different regions of the SARS-CoV-2 gene analyzed (Spike protein, ORF1ab, Nucleocapsid polyprotein, ect.) and the type of samples used in the studies. Most of the studies, especially those referred to as 

With the high infection numbers worldwide, the SARS-CoV-2 virus has evolved, developed mutations and given rise to new genetic variations with increased infectivity and transmissibility. Efforts are currently being undertaken to characterize the virus and its genomic variability molecularly. Viral mutations and variants around the globe are routinely monitored through sequence-based surveillance, epidemiological analysis and laboratory studies.

This study has examined the mutational profile of SARS-CoV-2 between December 2019 to October 2020 from 62 studies of different continents. The pooled prevalence of SARS-CoV-2 variants in COVID-19 patients' samples estimated by the random-effect model was 95.1%. Upon using the Trim and Fill method to adjust for potential bias, the estimate for the prevalence of the variants was still very high at 82.5%.

The analysis showed that between-study variability was high (I 2 = 98.95%). The subgroup meta-analysis showed that the high heterogeneity was contributed by countries such 'Worldwide' (I 2 = 99.7%), 'Multiple Countries' (I 2 = 95.2%), Hong Kong (I 2 = 93.7%) and USA (I 2 = 92.3%). Only two countries, Italy (I 2 = 0%) and China (I 2 = 5.4%) showed a low heterogeneity score. The different methods used to detect the mutations may contribute to the high heterogeneity, especially in the 'Worldwide' and 'Multiple Countries'. The high heterogeneity could also be attributed to the different regions of the SARS-CoV-2 gene analyzed (Spike protein, ORF1ab, Nucleocapsid polyprotein, ect.) and the type of samples used in the studies. Most of the studies, especially those referred to as 'Worldwide' and 'Multiple Countries', analyzed patients' genomic data downloaded from GISAID's database.

Most of the reported mutations were located at the Spike gene region, followed by the Nucleocapsid gene and ORF1ab gene. The high number of studies reporting on the Spike gene region might be due to its importance in the pathogenicity and transmissibility of the SARS-CoV-2 virus. The Spike (S) gene has two domains: S1 and S2. The S1 domain mediates receptor binding while S2 mediates downstream membrane fusion [74] . The S1 receptor-binding domain (RBD) shows a high affinity for the human ACE2 receptor in the lungs' alveolar type 2 (AT2) cells. Once the virus is attached to the host cell receptor, cleavage occurs between subunits S1 and S2. The subunit S2 will drive the viral and cellular membranes to fuse. The S1 recognizes and binds to the ACE2 receptor, whereas S2 directly facilitates entry into the host cell, making S1 and S2 crucial for infection [14] .

Data extracted from publications included in this study showed that a 23403A>G mutation in the S gene, which produced a missense mutation of D614G in the Spike protein, was recorded in 43 out of 62 studies. The D614G substitution is usually linked to three other mutations: a 241C>to-T mutation in the 5 -UTR region, a synonymous 3037C>T mutation, and a non-synonymous 14408C>T mutation at the RNA-dependent RNA polymerase (RdRP) known as P323L or P4715L at ORF1ab gene.

Our data showed that D614G was detected in the European region from middle to late February 2020 [51] . By early March, it had spread rapidly to the United States (US) [51] and the South American region [62] . In east Asia, the D614G variant was found in Thailand from a sample diagnosed with COVID-19 in early March 2020 [69] . While in China, the variant was detected in samples collected from January to April 2020 [25] . By June 2020, D614G was found in every sample sequenced worldwide [75] .

The mutation appeared to arise independently to simultaneously sweep across multiple geographic regions, suggestive of natural selection and an adaptive benefit of D614G. However, subsequent sequencing efforts identified the D614G mutation in viruses in several Chinese provinces in late January (first D614G in China: hCoV-19/Zhejiang/HZ103/2020; 24 January 2020), raising the possibility that global spreading of this mutation may result from chance founder events. Viruses carrying 614G mutation could initiate most early transmission events in multiple locations, demonstrating that D614G mutation was not adaptive, despite in vitro data showing its effects on receptor binding [76] .

A study of more than 25,000 sequences of the UK population found that viruses bearing 614G mutation are associated with higher viral load and younger age of patients. It appeared to spread faster and seed larger phylogenetic clusters than viruses with 614D; however, no association was found between the presence of the Spike 614G with clinical severity and COVID-19 mortality [65] .

In this study, few limitations were identified, including the inability to assess the impact of the identified mutations on patients' viral loads, severity of the disease, and its transmissibility, due to the lack of reported data from the included studies. An understanding of the impact of the mutations on these variables would be invaluable. Furthermore, most of the studies downloaded only viral genomic data extracted from COVID-19 patients from NCBI and GSAID websites, thus limiting our access to the patients' demographic information such as sex and age; and clinical data such as viral loads symptoms, co-morbidities and disease severity. The scarcity of the required data also limited the subgroup metaanalyses that could be conducted.

In this study, a systematic review and meta-analysis of studies were conducted to report the global prevalence of SARS-CoV-2 variants, estimated at 95.1%. Although a high heterogeneity was observed, we believe the estimate provides a good indication of the prevalence of SARS-CoV-2 variants worldwide from December 2019 to October 2020. With the fast evolution of the SARS-CoV-2 virus, there is a need to continuously monitor the prevalence of new mutations due to their potential influence on disease severity, transmissibility, resistance to antiviral drugs and vaccine effectiveness.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/ 10.3390/life11111224/s1, Table S1 : Major characteristics of the included studies; Table S2 : Search strategy in four electronic databases; Table S3 : Quality of included studies by JBI critical appraisal checklist for studies reporting prevalence data. 

Molecular Interaction Analysis of Sulawesi Propolis Compounds with SARS-CoV-2 Main Protease as Preliminary Study for COVID-19 Drug Discovery

Four SARS-CoV-2 Genome Sequences from Late

Point-of-Care Antigen and Molecular-Based Tests for Diagnosis of SARS-CoV-2 Infection. Cochrane Database Syst

The Biogrid Database: A Comprehensive Biomedical Resource of Curated Protein, Genetic, and Chemical Interactions

Immune-Boosting Role of Vitamins D, C, E, Zinc, Selenium and Omega-3 Fatty Acids: Could They Help against COVID-19? Maturitas

Time to Enhance Immunity Via Functional Foods and Supplements: Hope for SARS-CoV-2 Outbreak

COVID-19 and Nasal Cytobrush Cytology

Diagnosis and in-Line Treatment of COVID-19

Using the Spike Protein Feature to Predict Infection Risk and Monitor the Evolutionary Dynamic of Coronavirus

Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (Prisma-P) 2015: Elaboration and Explanation

Methodological Guidance for Systematic Reviews of Observational Epidemiological Studies Reporting Prevalence and Cumulative Incidence Data

Quantifying Heterogeneity in a Meta-Analysis

Coding-Complete Genome Sequences of Three SARS-CoV-2 Strains from

Naturally Occurring SARS-CoV-2 Gene Deletions Close to the Spike S1/S2 Cleavage Site in the Viral Quasispecies of Covid19 Patients

Genomic and Proteomic Mutation Landscapes of SARS-CoV-2

Multiscale Feedback Loops in SARS-CoV-2 Viral Evolution

SARS-CoV-2 Viral Spike G614 Mutation Exhibits Higher Case Fatality Rate

Evidence for Mutations in SARS-CoV-2 Italian Isolates Potentially Affecting Virus Transmission

Genomic Analysis and Comparative Multiple Sequences of SARS-CoV-2

Epidemiological and Genomic Analysis of SARS-CoV-2 in 10 Patients from a Mid-Sized City Outside of Hubei, China in the Early Phase of the COVID-19 Outbreak. Front

Whole-Genome Sequence of SARS-CoV-2 Isolate Siena-1/2020. Microbiol. Resour

Identification of the Nucleotide Substitutions in 62 SARS-CoV-2 Sequences from Turkey

Genome Analysis of SARS-CoV-2 Isolates Occurring in India: Present Scenario

Genomic Surveillance of COVID-19 Cases in Beijing

SARS-CoV-2 Genomic Characterization and Clinical Manifestation of the COVID-19 Outbreak in Uruguay

Mutation Density Changes in SARS-CoV-2 Are Related to the Pandemic Stage but to a Lesser Extent in the Dominant Strain with Mutations in Spike and Rdrp

Phylogeography of SARS-CoV-2 Pandemic in Spain: A Story of Multiple Introductions, Micro-Geographic Stratification, Founder Effects, and Super-Spreaders

SARS-CoV-2 Genomic Surveillance in Taiwan Revealed Novel Orf8-Deletion Mutant and Clade Possibly Associated with Infections in Middle East

Non-Synonymous Mutations of SARS-CoV-2 Leads Epitope Loss and Segregates Its Variants. Microbes Infect

Genomic Surveillance Revealed Prevalence of Unique SARS-CoV-2 Variants Bearing Mutation in the Rdrp Gene among Nevada Patients

Missense Mutations in SARS-CoV2 Genomes from Indian Patients

Analysis of Genomic Distributions of SARS-CoV-2 Reveals a Dominant Strain Type with Strong Allelic Associations

Intra-Host Non-Synonymous Diversity at a Neutralizing Antibody Epitope of SARS-CoV-2 Spike Protein N-Terminal Domain

Genome-Wide Analysis of SARS-CoV-2 Virus Strains Circulating Worldwide Implicates heterogeneity

Genomic Evolution of Severe Acute Respiratory Syndrome Coronavirus 2 in India and Vaccine Impact

Evolution of Viral Quasispecies During SARS-CoV-2 Infection

Two SARS-CoV-2 Genome Sequences of Isolates from Rural U.S. Patients Harboring the D614g Mutation

Genomic Characterization of a Novel SARS-CoV-2

Genome-Wide Identification and Characterization of Point Mutations in the SARS-CoV-2 Genome

The Progression of Sars Coronavirus 2 (SARS-CoV2): Mutation in the Receptor Binding Domain of Spike Gene

Variant Analysis of SARS-CoV-2 Genomes

Isolation and Phylogenetic Analysis of SARS-CoV-2 Variants Collected in Russia During the COVID-19 Outbreak

Comparative Genomic Analysis of Rapidly Evolving SARS-CoV-2 Reveals Mosaic Pattern of Phylogeographical Distribution

Genome Sequences of Six SARS-CoV-2 Strains Isolated in Morocco

Territorywide Study of Early Coronavirus Disease Outbreak

Temporal Mutational Profile Appearances of Swedish SARS-CoV-2 During the Early Pandemic. Viruses

High-Density Amplicon Sequencing Identifies Community Spread and Ongoing Evolution of SARS-CoV-2 in the Southern United States

Geographical Reconstruction of the SARS-CoV-2 Outbreak in Lombardy (Italy) During the Early Phase

Different Mutations in SARS-CoV-2 Associate with Severe and Mild Outcome

Emerging SARS-CoV-2 Mutation Hot Spots Include a Novel Rna-Dependent-Rna Polymerase Variant

Genetic Analysis of SARS-CoV-2 Isolates Collected from Bangladesh: Insights into the Origin, Mutational Spectrum and Possible Pathomechanism

Analysis of Indian SARS-CoV-2 Genomes Reveals Prevalence of D614g Mutation in Spike Protein Predicting an Increase in Interaction with Tmprss2 and Virus Infectivity

Phylogeography of 27,000 SARS-CoV-2 Genomes: Europe as the Major Source of the COVID-19 Pandemic

Genome-Wide Analysis of Indian SARS-CoV-2 Genomes for the Identification of Genetic Mutation and Snp

Genomic Exploration Light on Multiple Origin with Potential Parsimony-Informative Sites of the Severe Acute Respiratory Syndrome Coronavirus 2 in Bangladesh

Transmission Dynamics of SARS-CoV-2 within-Host Diversity in Two Major Hospital Outbreaks in South Africa

Global Transmission Network of SARS-CoV-2: From Outbreak to Pandemic

Unambiguous Rna Metagenome-Assembled Genome Sequence of a Unique SARS-CoV-2 Variant Encoding Spike S813i and Orf1a A859v Substitutions

A SARS-CoV-2 Variant with the 12-Bp Deletion at E Gene

Molecular Epidemiology Analysis of SARS-CoV-2 Strains Circulating in Romania During the First Months of the Pandemic

Genomic Analysis of Early SARS-CoV-2 Variants Introduced in Mexico

SARS-CoV-2 Genomic Variations Associated with Mortality Rate of COVID-19

Coding-Complete Genome Sequences of 23 SARS-CoV-2 Samples from the

Evaluating the Effects of SARS-CoV-2 Spike Mutation D614g on Transmissibility and Pathogenicity

Characterizing SARS-CoV-2 Mutations in the United States

Decoding Asymptomatic COVID-19 Infection and Transmission

Decoding SARS-CoV-2 Transmission and Evolution and Ramifications for COVID-19 Diagnosis, Vaccine, and Medicine

An Overview of the Genetic Variations of the SARS-CoV-2 Genomes Isolated in Southeast Asian Countries

Global Snp Analysis of 11,183 SARS-CoV-2 Strains Reveals High Genetic Diversity

Genomic Characterization of SARS-CoV-2 Identified in a Reemerging COVID-19 Outbreak in Beijing's Xinfadi Market in 2020

SARS-CoV-2 Samples May Escape Detection Because of a Single Point Mutation in the N Gene

Comprehensive Analyses of SARS-CoV-2 Transmission in a Public Health Virology Laboratory

SARS-CoV-2 Spike-Protein D614g Mutation Increases Virion Spike Density and Infectivity

Structural and Functional Analysis of the D614g SARS-CoV-2 Spike Protein Variant

Genetic Variants of SARS-CoV-2-What Do They Mean?

The authors declare no conflict of interest.